アブストラクト
| Title | 大腸癌肝転移の周術期化学療法 |
|---|---|
| Subtitle | 特集 周術期化学療法の現状と展望 |
| Authors | 岡崎聡, 石川敏昭, 植竹宏之* |
| Authors (kana) | |
| Organization | *東京医科歯科大学大学院・総合外科学 |
| Journal | 癌と化学療法 |
| Volume | 47 |
| Number | 4 |
| Page | 574-577 |
| Year/Month | 2020 / 4 |
| Article | 報告 |
| Publisher | 癌と化学療法社 |
| Abstract | 「要旨」 大腸癌肝転移の周術期化学療法には肝切除後の再発抑制や予後延長を目的として行う補助化学療法と, 切除不能な肝転移を手術に持ち込む「conversion」をめざした術前補助化学療法がある. 補助化学療法について全生存期間の延長に結び付くレジメンや施行時期は明らかになっていないが, 術後の5-FU/LV療法(静注または内服)による再発抑制効果が示されている. conversionをめざして行う術前補助化学療法では, FOLFOXやFOLFIRIとの分子標的薬併用療法またはFOL FOXIRI+bevacizumab療法で高い奏効率と肝切除率が期待できる. |
| Practice | 臨床医学：一般 |
| Keywords | Colorectal liver metastasis (CRLM), Perioperative chemotherapy, Conversion therapy |
- 全文ダウンロード： 従量制、基本料金制の方共に913円(税込) です。
参考文献
- 1) Adam R, Delvart V, Pascal G, et al: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240(4): 644-658, 2004.
- 2) Tanaka K, Shimada H, Ueda M, et al: Long-term charac-teristics of 5-year survivors after liver resection for co-lorectal metastases. Ann Surg Oncol 14(4): 1336-1346, 2007.
- 3) Nordlinger B, Sorbye H, Glimelius B, et al: Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal can-cer(EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14(12): 1208-1215, 2013.
- 4) Primrose J, Falk S, Finch-Jones M, et al: Systemic che-motherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 15(6): 601-611, 2014.
- 5) Portier G, Elias D, Bouche O, et al: Multicenter random-ized trial of adjuvant fluorouracil and folinic acid com-pared with surgery alone after resection of colorectal liv-er metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24(31): 4976-4982, 2006.
残りの9件を表示する
- 6) Hasegawa K, Saiura A, Takayama T, et al: Adjuvant oral uracil-tegafur with leucovorin for colorectal cancer liver metastases: a randomized controlled trial. PLoS One 11(9): e0162400, 2016.
- 7) Tournigand C, Andre T, Achille E, et al: FOLFIRI fol-lowed by FOLFOX6 or the reverse sequence in ad-vanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(2): 229-237, 2004.
- 8) Wong R, Cunningham D, Barbachano Y, et al: A multi-centre study of capecitabine, oxaliplatin plus bevacizu-mab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for up-front resection. Ann Oncol 22(9): 2042-2048, 2011.
- 9) Folprecht G, Gruenberger T, Bechstein WO, et al: Tu-mour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11(1): 38-47, 2010.
- 10) Folprecht G, Gruenberger T, Bechstein W, et al: Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept(CELIM study). Ann Oncol 25(5): 1018-1025, 2014.
- 11) Oki E, Emi Y, Yamanaka T, et al: Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorec-tal liver metastasis(ATOM trial). Br J Cancer 121(3): 222-229, 2019.
- 12) Sunakawa Y, Tsuji A, Fujii M, et al: No benefit from the addition of anti-EGFR antibody in all right-sided meta-static colorectal cancer? Ann Oncol 28(8): 2030-2031, 2017.
- 13) Gruenberger T, Bridgewater J, Chau I, et al: Bevacizu-mab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol 26(4): 702-708, 2015.
- 14) Tomasello G, Petrelli F, Ghidini M, et al: FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. JAMA Oncol 3(7): e170278, 2017.
